BridgeBio Pharma, Inc. (BBIO) stock
BBIONasdaqPharmaceutical PreparationsFiscal year ends December 31
$76.80−0.56 (-0.72%)
Close on Nov 17, 2026Market cap $14.96BP/E –Yield –
BridgeBio Pharma operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
BridgeBio Pharma's operating income for the twelve months ending Sep 30, 2026 was -$364.24M. For fiscal 2025 it was -$523.41M. The highest annual figure on record is -$43.86M in fiscal 2017.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$523.41M | – |
| FY2024 | Dec 31, 2024 | -$592.97M | – |
| FY2023 | Dec 31, 2023 | -$607.37M | – |
| FY2022 | Dec 31, 2022 | -$512.20M | – |
| FY2021 | Dec 31, 2021 | -$576.63M | – |
| FY2020 | Dec 31, 2020 | -$474.48M | – |
| FY2019 | Dec 31, 2019 | -$266.24M | – |
| FY2018 | Dec 31, 2018 | -$183.66M | – |
| FY2017 | Dec 31, 2017 | -$43.86M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -$11.64M | – |
| Q2 FY2026 | Jun 30, 2026 | -$107.08M | – |
| Q1 FY2026 | Mar 31, 2026 | -$105.96M | – |
| Q4 FY2025 | Dec 31, 2025 | -$139.56M | – |
| Q3 FY2025 | Sep 30, 2025 | -$145.20M | – |
| Q2 FY2025 | Jun 30, 2025 | -$134.28M | – |
| Q1 FY2025 | Mar 31, 2025 | -$104.37M | -30529.2% |
| Q4 FY2024 | Dec 31, 2024 | -$226.03M | – |
| Q3 FY2024 | Sep 30, 2024 | -$191.75M | – |
| Q2 FY2024 | Jun 30, 2024 | -$175.54M | – |
| Q1 FY2024 | Mar 31, 2024 | $343.00K | – |
| Q4 FY2023 | Dec 31, 2023 | -$177.42M | – |
| Q3 FY2023 | Sep 30, 2023 | -$157.69M | – |
| Q2 FY2023 | Jun 30, 2023 | -$146.10M | – |
| Q1 FY2023 | Mar 31, 2023 | -$126.16M | – |
| Q4 FY2022 | Dec 31, 2022 | -$129.23M | – |
| Q3 FY2022 | Sep 30, 2022 | -$129.12M | – |
| Q2 FY2022 | Jun 30, 2022 | -$80.18M | – |
| Q1 FY2022 | Mar 31, 2022 | -$173.68M | – |
| Q4 FY2021 | Dec 31, 2021 | -$165.61M | – |
| Q3 FY2021 | Sep 30, 2021 | -$149.50M | – |
| Q2 FY2021 | Jun 30, 2021 | -$94.02M | – |
| Q1 FY2021 | Mar 31, 2021 | -$167.50M | – |
| Q4 FY2020 | Dec 31, 2020 | -$127.49M | – |
| Q3 FY2020 | Sep 30, 2020 | -$119.94M | – |
| Q2 FY2020 | Jun 30, 2020 | -$124.57M | – |
| Q1 FY2020 | Mar 31, 2020 | -$102.49M | – |
| Q4 FY2019 | Dec 31, 2019 | -$78.64M | – |
| Q3 FY2019 | Sep 30, 2019 | -$54.53M | – |
| Q2 FY2019 | Jun 30, 2019 | -$69.32M | – |
| Q1 FY2019 | Mar 31, 2019 | -$63.75M | – |
| Q4 FY2018 | Dec 31, 2018 | -$65.58M | – |
| Q3 FY2018 | Sep 30, 2018 | -$41.46M | – |
See a number that looks wrong?